ImmVirX Presents Promising Clinical Data on IVX037 at ESMO 2025, Highlighting Activity in MSS-CRC and Ovarian Cancer
Intratumoural IVX037 showed encouraging biological and clinical activity in microsatellite stable colorectal cancer (MSS-CRC), both as a monotherapy and in combination with the PD-1 inhibitor sintilimab, particularly in KRAS/BRAF-mutant tumours. Disease control was observed in several MSS-CRC patients with liver metastases, especially those harbouring KRAS/BRAF mutations. IVX037 treatment demonstrated abscopal effects, with responses in liver, […]
